Two Readings of One Eosinophil Count: Choosing a First Biologic for Severe Asthma
A florist with severe, poorly controlled asthma tests positive for both an allergic and an eosinophilic pathway. The disagreement isn't about whether she qualifies for a biologic — she qualifies for more than one — it's about which number in her chart is actually doing the work.
Renata S., a 42-year-old florist, has run her own small shop for eleven years, working most days elbow-deep in cut stems, potting soil, and the dust that collects in a back room nobody has fully cleared out since she took over the lease. She was diagnosed with asthma in her twenties and has had seasonal rhinitis for as long as she can remember, but the last year has been different: four courses of oral prednisone, two emergency-department visits, and a growing sense that the shop itself might be part of the problem, even though she has never wanted to consider closing it.
Her workup, done properly rather than assumed, found real signal in two directions at once. Skin testing came back positive to dust mite and cat dander — both perennial, both plausible in a building she can't fully control — with a total IgE of 245 IU/mL, comfortably inside the range omalizumab's dosing table was built around. Her blood eosinophil count, drawn on a day she was not on oral steroids, came back at 420 cells/µL, well above the threshold MENSA used to show mepolizumab cut exacerbations, and her FeNO of 52 ppb sits high enough to suggest a genuinely type-2-high process rather than a borderline one — read against a normal body mass index and no diabetes or cardiac history, meaning none of the comorbid confounders that usually blur a workup like hers are in play. She is, in the plainest sense, eligible for either drug class on paper. The argument in front of the team is about which number is actually driving her disease, because giving the wrong one primacy means starting a drug that treats a real but secondary pathway while the dominant one keeps firing.
Her mother had adult-onset asthma as well, diagnosed in her fifties, though nobody in the family was ever formally phenotyped the way Renata is being now. EXTRA, the trial the team keeps returning to, didn't just show omalizumab worked in general; its own biomarker-stratified analysis found the benefit concentrated in patients resembling her specific combination of elevated FeNO and blood eosinophilia, which is exactly why her chart reads as a genuine two-pathway case rather than a one-sided one with noise attached.
Clinic visit, deciding between two eligible drug classes
Start with omalizumab. She has a real, perennial allergic sensitization — not a borderline trace reaction — and an IgE and weight combination squarely inside the labeled dosing table. EXTRA, the trial that best characterizes who actually benefits from anti-IgE, found the exacerbation reduction concentrated in patients with a biomarker-high profile that included elevated FeNO, and hers is 52. Her allergic sensitization isn't incidental — it's the pathway her own workup points to first.
If her eosinophils were the only positive finding here, I wouldn't be making this argument the same way — a purely non-allergic eosinophilic patient with a negative skin test has no case for anti-IgE at all. The reason this is even a real debate is that she has both, and omalizumab is the drug that treats the pathway her environment is actually feeding.
I'd weight the eosinophil count higher than the IgE here, and not by a small margin. 420 cells/µL is well past the threshold MENSA used to demonstrate benefit, and unlike her IgE, it was drawn while she was off oral corticosteroids, so it isn't artificially suppressed. A count that high in a patient with four steroid courses this year is the number I'd want to silence first.
The EXTRA subgroup analysis is real, but it was built to identify likely omalizumab responders among patients already selected for allergic asthma — it wasn't designed to adjudicate between omalizumab and an anti-IL-5 agent in a patient positive for both. Reading it as settling that comparison asks more of the trial than it was built to answer.
Both of you are reading a real number correctly and neither reading is wrong on its own terms — which is exactly why I'd let magnitude, not presence, break the tie. Her eosinophil count isn't just above the MENSA cutoff, it's nearly three times it; her IgE, while genuinely positive, sits in the lower-middle of the omalizumab dosing range rather than at an extreme that would suggest an unusually IgE-driven process. When both pathways are positive but one number is quantitatively more extreme than the other, that's the more defensible place to start.
Dupilumab was raised and set aside for now, not because it's wrong on the biology — her FeNO alone would support it — but because starting with the agent whose own trial population match is the clearest gives us a cleaner read on response before adding a third candidate mechanism to the picture.
Agreed: mepolizumab started today, with a structured 4-month response check — exacerbation frequency, oral steroid courses, and a repeat symptom score — before declaring it a success or failure.
Not agreed, and left explicitly open rather than smoothed over: whether a partial but incomplete response at four months should prompt adding anti-IgE on top of mepolizumab or switching to it outright. The allergist would rather add; the pulmonologist would rather switch and see the eosinophil-pathway drug cleared entirely before reintroducing IgE as a variable. Neither position was overruled — the plan simply doesn't need an answer to that question until the four-month mark.